Meso Developing Active

Biotech resurgence: M&A activity and market performance

Score
0.4
Velocity
▲ 0.0
Articles
13
Sources
2

Summary

An article belongs to this narrative if it discusses the resurgence of biotech markets, focusing on M&A activity and overall market performance.

Related Articles

This Biotech Was Quietly Bought Before a $58 Per Share Takeout

Yahoo Finance · Mar 21, 2026
Mixed

This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year

Nasdaq · Mar 20, 2026
Mixed

My Top 3 Drug Stocks for March 2026

Nasdaq · Mar 20, 2026
Bearish

Why biotech is back: IBT portfolio manager’s view

Yahoo Finance · Mar 20, 2026
Mixed

Sources

MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s … Yahoo Finance
2 Healthcare Stocks That Could Soar Over the Next 5 … Nasdaq
Moderna Stock is Soaring. Is It Too Late to Buy? Nasdaq
Two Biotech Stocks Hover Near Highs; Natural Gas And Finance … Yahoo Finance
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but … Nasdaq
This Biotech Was Quietly Bought Before a $58 Per Share … Yahoo Finance
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, … Yahoo Finance
This $91 Million Position Signals Conviction in a Biotech Stock … Nasdaq
My Top 3 Drug Stocks for March 2026 Nasdaq
2 Healthcare Stocks to Buy Before They Get Bought Out Nasdaq
Why biotech is back: IBT portfolio manager’s view Yahoo Finance

Timeline

Last Updated Mar 20, 2026